Skip to main content
Top
Published in: Supportive Care in Cancer 3/2006

01-03-2006 | Original Article

Infections in a pediatric patient cohort with acute lymphoblastic leukemia during the entire course of treatment

Authors: Katerina Katsimpardi, Vassilios Papadakis, Anastasia Pangalis, Agapi Parcharidou, John P. Panagiotou, Michael Soutis, Evangelos Papandreou, Sophia Polychronopoulou, Stavros Haidas

Published in: Supportive Care in Cancer | Issue 3/2006

Login to get access

Abstract

Goals

To assess the type, frequency, severity, and outcome of all infectious episodes in a pediatric patient cohort with acute lymphoblastic leukemia (ALL) from a single institution during the entire length of leukemia treatment.

Patients and methods

Eighty-six patients were treated according to a modified ALL Berlin–Frankfurt–Munster protocol. Retrospective analysis of all types of infections according to the treatment phase and the degree of neutropenia is presented.

Results

A total of 610 infectious episodes were recorded. Most infections were documented during maintenance (57%), followed by the induction phase (20.3%). During maintenance, 347 episodes were encountered, with nonspecific viral upper respiratory tract infections (URIs) being the commonest diagnosis (40.0%). Additionally, 38 of 58 total specific viral infections occurred during maintenance: 16 herpes simplex, 7 varicella, 10 herpes zoster infections [varicella–zoster virus (VZV), 45%]. The majority of bacteremia and fever of unknown origin occurred during induction (20%). The number of Gram-negative bacteremia was 50% of the total (26 of 52). The majority of the infections (59.5%) occurred without neutropenia [absolute neutrophil count (ANC) >1,000 μl−1]. Fewer infections (9.3%) were recorded with concurrent very severe neutropenia (ANC <100 μl−1), although 38.5% of positive blood cultures were documented with severe neutropenia. No infection-related fatality occurred.

Conclusions

Most of the severe infections occurred during induction. Gram-positive bacteremia and Gram-negative bacteremia were almost equal. URIs were the commonest infections during the entire treatment and during maintenance. Specific viral infections represented a smaller percentage of the total (VZV was the commonest pathogen). Infectious complications represented a significant morbidity factor, but notably, mortality was negligible.
Literature
1.
go back to reference Alexander SW, Walsh TJ, Freifeld AG, Pizzo PA (2002) Infectious complications in pediatric cancer patients. In: Pizzo PA, Poplack DG (eds) Principles and practice of pediatric oncology. Lippincot Williams & Wilkins, Philadelphia, pp 1239–1283 Alexander SW, Walsh TJ, Freifeld AG, Pizzo PA (2002) Infectious complications in pediatric cancer patients. In: Pizzo PA, Poplack DG (eds) Principles and practice of pediatric oncology. Lippincot Williams & Wilkins, Philadelphia, pp 1239–1283
2.
go back to reference Aquino VM, Pappo A, Buchanan GR et al (1995) The changing epidemiology of bacteremia in neutropenic children with cancer. Pediatr Infect Dis J 14:140–143PubMed Aquino VM, Pappo A, Buchanan GR et al (1995) The changing epidemiology of bacteremia in neutropenic children with cancer. Pediatr Infect Dis J 14:140–143PubMed
3.
go back to reference Balfour HH Jr (1991) Varicella–zoster virus infections in the immunocompromised host. Natural history and treatment. Scand J Infect Dis Suppl 80:69–74PubMed Balfour HH Jr (1991) Varicella–zoster virus infections in the immunocompromised host. Natural history and treatment. Scand J Infect Dis Suppl 80:69–74PubMed
4.
go back to reference Bodey GP, Buckley M, Sathe YS, Freireich EJ (1996) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340 Bodey GP, Buckley M, Sathe YS, Freireich EJ (1996) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340
5.
go back to reference Donowitz GR, Maki DG, Crnich CJ et al (2001) Infections in the neutropenic patient—new views of an old problem. Hematology (Am Soc Hematol Educ Program) 113–139 Donowitz GR, Maki DG, Crnich CJ et al (2001) Infections in the neutropenic patient—new views of an old problem. Hematology (Am Soc Hematol Educ Program) 113–139
6.
go back to reference Giamarellou H, Antoniadou A (2001) Infectious complications of febrile leukopenia. Infect Dis Clin North Am 15:457–482CrossRefPubMed Giamarellou H, Antoniadou A (2001) Infectious complications of febrile leukopenia. Infect Dis Clin North Am 15:457–482CrossRefPubMed
7.
go back to reference Haidas S, Grafakos S, Ziva M et al (1984) Infections in leukemic children. Ann Clin Pediatr Univ Atheniensis 31:100–107 Haidas S, Grafakos S, Ziva M et al (1984) Infections in leukemic children. Ann Clin Pediatr Univ Atheniensis 31:100–107
8.
go back to reference Hughes WT, Armstrong D, Bodey GP et al (1997) 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 25:551–573PubMed Hughes WT, Armstrong D, Bodey GP et al (1997) 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 25:551–573PubMed
9.
go back to reference Karthaus M, Doellmann T, Klimasch T et al (2002) Central venous catheter infections in patients with acute leukemia. Chemotherapy 48:154–157CrossRefPubMed Karthaus M, Doellmann T, Klimasch T et al (2002) Central venous catheter infections in patients with acute leukemia. Chemotherapy 48:154–157CrossRefPubMed
10.
go back to reference Kostaridou S, Polychronopoulou S, Psarra K et al (2004) Decrease of CD4+ and B-lymphocyte population is not associated with severe infectious complications in children with acute lymphoblastic leukemia during maintenance. Int J Hematol 80:354–360CrossRefPubMed Kostaridou S, Polychronopoulou S, Psarra K et al (2004) Decrease of CD4+ and B-lymphocyte population is not associated with severe infectious complications in children with acute lymphoblastic leukemia during maintenance. Int J Hematol 80:354–360CrossRefPubMed
11.
go back to reference Lex C, Korholz D, Kohlmuller B et al (2001) Infectious complications in children with acute lymphoblastic leukemia and T-cell lymphoma—a rationale for tailored supportive care. Support Care Cancer 9:514–521CrossRefPubMed Lex C, Korholz D, Kohlmuller B et al (2001) Infectious complications in children with acute lymphoblastic leukemia and T-cell lymphoma—a rationale for tailored supportive care. Support Care Cancer 9:514–521CrossRefPubMed
12.
go back to reference Meir HM, Balawi IA, Meer HM et al (2001) Fever and granulocytopenia in children with acute lymphoblastic leukemia under induction therapy. Saudi Med J 22(5):423–427PubMed Meir HM, Balawi IA, Meer HM et al (2001) Fever and granulocytopenia in children with acute lymphoblastic leukemia under induction therapy. Saudi Med J 22(5):423–427PubMed
13.
go back to reference Papadakis V, Panagiotou PI, Polychronopoulou S et al (2003) Results of childhood acute lymphoblastic leukemia treatment in Greek patients using a BFM-based protocol. Haema 6:208–216 Papadakis V, Panagiotou PI, Polychronopoulou S et al (2003) Results of childhood acute lymphoblastic leukemia treatment in Greek patients using a BFM-based protocol. Haema 6:208–216
14.
go back to reference Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323–1332CrossRefPubMed Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323–1332CrossRefPubMed
15.
go back to reference Pizzo PA, Rubin M, Freifeld A, Walsh TJ (1991) The child with cancer and infection I. Empirical therapy for fever and neutropenia, and preventive strategies. J Paediatr 119:679–694 Pizzo PA, Rubin M, Freifeld A, Walsh TJ (1991) The child with cancer and infection I. Empirical therapy for fever and neutropenia, and preventive strategies. J Paediatr 119:679–694
16.
go back to reference Pizzo PA, Rubin M, Freifeld A, Walsh TJ (1991) The child with cancer and infection II. Nonbacterial infections. J Paediatr 119:845–857 Pizzo PA, Rubin M, Freifeld A, Walsh TJ (1991) The child with cancer and infection II. Nonbacterial infections. J Paediatr 119:845–857
17.
go back to reference Polychronopoulou S, Panagiotou PI, Raftopoulou A et al (1994) Prevalence of Gram (+) microorganisms in septicemias in immunocompromised children. Paediatriki 17:75 (abstr) Polychronopoulou S, Panagiotou PI, Raftopoulou A et al (1994) Prevalence of Gram (+) microorganisms in septicemias in immunocompromised children. Paediatriki 17:75 (abstr)
19.
go back to reference Pui CH, Ribeiro RC (2003) International collaboration on childhood leukemia. Int J Hematol 78:383–389PubMed Pui CH, Ribeiro RC (2003) International collaboration on childhood leukemia. Int J Hematol 78:383–389PubMed
20.
go back to reference Rackoff WR, Ge J, Sather HN, Cooper HA, Hutchinson RJ, Lange BJ (1999) Central venous catheter use and the risk of infection in children with acute lymphoblastic leukemia: a report from the Children’s Cancer Group. J Pediatr Hematol/Oncol 21(4):260–267CrossRef Rackoff WR, Ge J, Sather HN, Cooper HA, Hutchinson RJ, Lange BJ (1999) Central venous catheter use and the risk of infection in children with acute lymphoblastic leukemia: a report from the Children’s Cancer Group. J Pediatr Hematol/Oncol 21(4):260–267CrossRef
21.
go back to reference Rahiala J, Perkkiö M, Riikonen P (1998) Infections occurring during the courses of anticancer chemotherapy in children with ALL. Pediatr Hematol Oncol 15:165–174PubMed Rahiala J, Perkkiö M, Riikonen P (1998) Infections occurring during the courses of anticancer chemotherapy in children with ALL. Pediatr Hematol Oncol 15:165–174PubMed
23.
go back to reference Schrappe M, Reiter A, Ludwig WD et al (2000) Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90.German–Austrian–Swiss ALL-BFM Study Group. Blood 95:3310–3322PubMed Schrappe M, Reiter A, Ludwig WD et al (2000) Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90.German–Austrian–Swiss ALL-BFM Study Group. Blood 95:3310–3322PubMed
24.
go back to reference Wehl G, Allerberger F, Heitger A et al (1999) Trends in infection morbidity in a pediatric oncology ward, 1986–1995. Med Pediatr Oncol 32:336–343CrossRefPubMed Wehl G, Allerberger F, Heitger A et al (1999) Trends in infection morbidity in a pediatric oncology ward, 1986–1995. Med Pediatr Oncol 32:336–343CrossRefPubMed
25.
go back to reference Wood DJ, Corbitt G (1985) Viral infections in childhood leukemia. J Infect Dis 152:266–273PubMed Wood DJ, Corbitt G (1985) Viral infections in childhood leukemia. J Infect Dis 152:266–273PubMed
26.
go back to reference Zinner SH (1999) Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 29:490–494PubMed Zinner SH (1999) Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 29:490–494PubMed
Metadata
Title
Infections in a pediatric patient cohort with acute lymphoblastic leukemia during the entire course of treatment
Authors
Katerina Katsimpardi
Vassilios Papadakis
Anastasia Pangalis
Agapi Parcharidou
John P. Panagiotou
Michael Soutis
Evangelos Papandreou
Sophia Polychronopoulou
Stavros Haidas
Publication date
01-03-2006
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 3/2006
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-005-0884-6

Other articles of this Issue 3/2006

Supportive Care in Cancer 3/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine